An observational study in Down Syndrome and Dysphagia, Oropharyngeal, sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Colorado, Denver · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Down Syndrome by University of Colorado, Denver — 4 open to participants now, 4 under way, 1 of them phase 3. Down Syndrome · University of Colorado, Denver.
Among the 12 studies in Down Syndrome by University of Colorado, Denver, this one is one of 2 that started in 2020, is one of 5 observational ones, and was the 8th registered.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
Browse Down Syndrome studies →4 of the 12 studies in Down Syndrome by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 6–22
University of Colorado, Denver · Sites in United States
Ages 18–50 · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 6 mo–89 yrs · Healthy volunteers
University of Colorado, Denver · Sites in United States
By country, each count listing its studies:
Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 158 across 145 observational studies indexed under Down Syndrome.
Median enrollment 47 across the 7 interventional studies, 800 across the 5 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Down Syndrome by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to learn more about tests that can assess lung health in children with Down syndrome.
Children aged 3-18 years (inclusive) with a diagnosis of Down syndrome who have had a swallow study in the previous 5 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
Total airway resistance
Airway resistance (R5) measured using forced oscillation technique at 5 Hertz
Time frame: Baseline
Airway reactance
Airway reactance (X5) measured using forced oscillation technique at 5 Hertz
Time frame: Baseline
Change in total airway resistance after albuterol
Airway resistance (R5) measured using forced oscillation technique at 5 Hertz before and after administration of albuterol
Time frame: Baseline
Change in airway reactance after albuterol
Airway reactance (X5) measured using forced oscillation technique at 5 Hertz before and after administration of albuterol
Time frame: Baseline
Health-related quality of life, as measured by the Pediatric Quality of Life Inventory
The Pediatric Quality of Life Inventory (PedsQL) assesses four domains of quality of life. Results are converted to a score from 0-100, where low numbers are low quality of life and higher numbers is better quality of life.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2020 to primary completion in Oct 2025, 61 months.
Of 40 non-industry observational studies under Down Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's 61 months is above that.
Counting every sponsor, half of 55 studies reached it within 34 months; a quarter within 19 and three quarters within 71.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Aug 2024 → Oct 2025 and completion Dec 2024 → Oct 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →